Research on HIV/AIDS Drug Resistance Testing
- Genotypic Test Matches Tropism Test in Predicting Who Benefits From CCR5 Inhibitors (July 28, 2009)
A genotypic test is just as accurate as a more expensive tropism test in determining which treatment-experienced patients are suitable for treatment with the CCR5 inhibitor maraviroc, researchers from the University of British Columbia reported.
From aidsmap.com
- Genetic Test Predicts Response to Maraviroc in Treatment-Experienced HIV Patients (July 22, 2009)
To read PDF, click here
From British Columbia Centre for Excellence in HIV/AIDS
- Abacavir Hypersensitivity Test Could Be Combined With Drug Resistance Test: Study (June 4, 2007)
From aidsmap.com
- HIV Test May Show Which Drugs Work Best (January 8, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Resistance Testing Can Level the Playing Field for People Starting Treatment, Study Says (May 4, 2006)
From aidsmap.com
- More Sensitive Drug-Resistance Tests Yield Higher Rates of Multidrug Resistance in Treatment-Naive Patients (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- Researchers Examine Use of Artificial Intelligence to Select Ideal Regimens for Treatment-Experienced Patients (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Small Study Suggests Genotypic Resistance Tests Maintain Accuracy Even When Viral Load Is Below 1,000 (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Drug Resistance Testing in Treatment-Naive Patients Is Cost-Effective, May Extend Lives, Study Says (September 26, 2005)
[Archived Article]
From Infectious Diseases Society of America
- Antivirogram vs. PhenoSense Assays (April 2005)
[Archived Article]
The two differ significantly for some NRTIs, but not for NNRTIs or protease inhibitors, a study finds.
From The Body PRO
- Drug Resistance as Measured by Single vs. Multiple Genotypic Tests Over Time (April 2005)
[Archived Article]
A study finds benefits to retaining all of a patient's resistance test results and complete treatment history.
From The Body PRO
- Little Difference Between Resistance Testing Methods in Treatment-Experienced Patients (February 10, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Enfuvirtide Benefits Confirmed at 48 Weeks (July 16, 2003)
[Archived Article]
Resistance testing is also found to be a reliable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Using Genotypic Inhibitory Quotient to Measure Response to Boosted-Amprenavir Regimen (July 15, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- The Inhibitory Quotient in Tipranavir/Ritonavir (July 14, 2003)
[Archived Article]
Therapeutic drug monitoring and phenotypic resistance testing are also found to be a valuable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Prediction of NRTI Options by Linking Reverse Transcriptase Genotype to Phenotypic Breakpoints (February 11, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Research From the 42nd ICAAC: Resistance Tests Compared; Amprenavir Is Guinea Pig (December 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Phenotyping and Therapeutic Drug Monitoring Complement Genotyping in Optimizing Therapy for HIV Patients (October 26, 2002)
[Archived Article]
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Genotyping Less Effective at Predicting Effective Regimens in Children (October 4, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Digging Deeper at the Resistance Workshop (August 14, 2002)
[Archived Article]
Key clinical findings from July's XI International HIV Drug Resistance Workshop.
From International AIDS Society
- Antiretroviral-Drug Resistance Among Patients Recently Infected With HIV (August 8, 2002)
[Archived Article]
Greater primary resistance necessitates earlier drug-resistance testing, researchers say.
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- The GUESS Study: An International Evaluation of the Accuracy, Precision and Consistency of Expert HIV-1 Genotype Interpretation (July 11, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- The ENVA-3 World Wide Evaluation Study Shows Extensive Differences in Interpretation on HIV-1 Genotype Analysis (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- The Role of Resistance Testing in an Inner-City Population (Fall 2001)
[Archived Article]
To read PDF, click here
In CRIA Update, from AIDS Community Research Initiative of America
- HIV Resistance Testing Proves Its Value (September 1999)
[Archived Article]
In Project Inform Perspective, from Project Inform
- Genotypic and Phenotypic Resistance Testing (Summer 1999)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Evaluating Drug Resistance Tests (Spring 1999)
[Archived Article]
In CRIA Update, from AIDS Community Research Initiative of America
- The State of Resistance Testing (Winter 1999/2000)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
|
|
Advertisement
|
E-Mail
Glossary
Share
